Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PentixaFor PET in CNS Lymphoma
NCT05222269Phase 2Terminated
- Sponsor
- Pentixapharm
- Start
- Oct 2022
- Primary completion
- Jan 2023
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of pentixafor in central nervous system lymphoma, sponsored by Pentixapharm. Started Oct 2022; status: terminated.
02
Drugs
pentixafor
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT05222269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05222269.